Elizabeth Warren (D-MA) and 25 other US senators wrote a letter to Department of Health and Human Services (HHS) Secretary Xavier Becerra requesting that the agency implements march-in rights for Astellas’ and Pfizer’s prostate cancer drug Xtandi. This would allow the federal government to take ownership of the drug’s license on the basis that government funding paid for part of its development.
According to Gail Dutton, “Sen. Warren has written six letters in the past two years urging HHS to establish march-in rights for Xtandi, despite HHS rejecting such requests in 2016 and 2017. In 2019, the U.S. Army also rejected such a request. In fact, no request for the U.S. government to exercise march-in rights has ever been granted.”
To read more, click here.
(Source: PharmaLive.com, January 25th, 2023)